Skip to main content
MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. logo

MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 688062 ISIN · CNE100005RD2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 541 across all filing types
Latest filing 2025-05-20 Annual Report
Country CN China
Listing Shanghai Stock Exchange 688062

About MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.

https://www.mabwell.com/en/

Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of therapeutic antibodies and innovative biologics. The company maintains an integrated R&D and manufacturing platform covering the full drug lifecycle, from target discovery and preclinical research to clinical development and commercial production. Its therapeutic pipeline addresses critical needs in oncology, autoimmune diseases, metabolic disorders, ophthalmology, and infectious diseases. Mabwell leverages proprietary technology platforms, including antibody-drug conjugates (ADCs), bispecific antibodies, and high-throughput screening, to develop a diverse portfolio of novel drug candidates and biosimilars. The organization is committed to delivering high-quality, accessible therapeutic solutions through its end-to-end biotechnological capabilities.

Recent filings

Filing Released Lang Actions
国泰海通证券股份有限公司关于迈威（上海）生物科技股份有限公司2024年报告的信息披露监管问询函的专项核查意见
Annual Report Classification · 95% confidence The document is a detailed regulatory inquiry response and special inspection opinion from Guotai Huatong Securities Co., Ltd. regarding the 2024 annual report of Maiwei (Shanghai) Biotechnology Co., Ltd. It contains extensive financial data, product sales analysis, market conditions, R&D progress, and risk assessments related to the company's 2024 fiscal year. The document references the 2024 annual report multiple times and provides detailed financial and operational information consistent with an annual report. The length (15,000 characters) and depth of content indicate this is the report itself, not merely an announcement or certification. Therefore, the document fits the definition of an Annual Report (10-K).
2025-05-20 Chinese
迈威生物关于2024年报告的信息披露监管问询函的回复公告
Management Reports Classification · 95% confidence The document is a detailed reply to a regulatory inquiry regarding the company's 2024 annual report. It contains extensive financial data, product sales figures, market analysis, and management's discussion on business performance and outlook. The document references the 2024 annual report multiple times and provides detailed explanations about revenue, costs, product performance, and future plans. It is not a brief announcement or a certification letter but a substantive management discussion and analysis related to the annual report. Therefore, it fits best into the category of Management Reports (MDA), which covers management's detailed explanation of financial results, business trends, and outlook. The document length (15,000 characters) and content depth support this classification with high confidence.
2025-05-20 Chinese
安永华明会计师事务所（特殊普通合伙）就上海证券交易所《关于对迈威（上海）生物科技股份有限公司2024 年报告的信息披露监管问询函》中部分涉及财务报表项目问询意见的专项说明
Annual Report Classification · 95% confidence The document is a detailed response to a regulatory inquiry from the Shanghai Stock Exchange's Science and Technology Innovation Board Company Management Department regarding the 2024 annual report of Maiwei (Shanghai) Biotechnology Co., Ltd. It includes extensive financial data, product sales analysis, revenue breakdowns, and explanations related to the company's 2024 financial performance. The document references an audit report issued by Ernst & Young Hua Ming LLP for the 2024 fiscal year, indicating it is related to the annual financial statements. The content is substantive, covering financial results, business operations, and management explanations for the fiscal year 2024, consistent with an Annual Report. It is not a brief announcement or a certification letter but a comprehensive financial and operational report. Therefore, the document should be classified as an Annual Report (10-K).
2025-05-20 Chinese
迈威生物关于公司董事长兼总经理收到立案告知书的公告
Legal Proceedings Report Classification · 95% confidence The document is an announcement regarding the receipt of a formal investigation notice (立案告知书) by the company's chairman and general manager from the China Securities Regulatory Commission (CSRC) due to suspected short-term trading. It is a regulatory announcement about a legal/regulatory proceeding involving a senior executive. The document does not contain financial data, report content, or meeting materials. It is not a full audit report, annual report, or earnings release. It is not a management or board change announcement per se, but rather a legal proceeding update. Therefore, the most appropriate classification is Legal Proceedings Report (LTR). The document length is short and focused on regulatory/legal matters, not a report publication or certification.
2025-05-09 Chinese
迈威生物2025年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2025 First Quarter Report" of a company, indicating it is a quarterly financial report. It contains detailed financial data such as revenue, net profit, cash flow, R&D expenses, and shareholder information. The report explicitly states it is unaudited and includes comprehensive financial metrics and analysis for the quarter. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data. The document is not a brief announcement or a certification, but a full quarterly report with detailed financials and shareholder data.
2025-04-28 Chinese
迈威生物关于对全资子公司泰康生物增资的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the capital increase (增资) of a wholly-owned subsidiary by the parent company. It details the amount of capital injection, the board approval, the subsidiary's financial data, and the impact and risk analysis of the capital increase. There is no indication that this is a full financial report, audit report, or earnings release. The document is a formal announcement about a financing activity related to capital structure changes. Therefore, it fits best under the category 'Capital/Financing Update' (CAP). The document length is short (1870 characters), but it contains substantive information about the capital increase, not just a notice of report publication or a certification. Hence, it is not RPA or RNS.
2025-04-28 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.